Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jaguar Health Reports First Quarter 2024 Financial Results

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately...

JAGX : 0.2585 (-9.84%)
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track

JAGX : 0.2585 (-9.84%)
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company

To register for the webinar, click here

JAGX : 0.2585 (-9.84%)
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website

SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality...

JAGX : 0.2585 (-9.84%)
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA

JAGX : 0.2585 (-9.84%)
FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development...

FLHLF : 0.0398 (+11.48%)
JAGX : 0.2585 (-9.84%)
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

/CNW/ - Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a...

JAGX : 0.2585 (-9.84%)
FLHLF : 0.0398 (+11.48%)
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions

Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee

JAGX : 0.2585 (-9.84%)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock...

JAGX : 0.2585 (-9.84%)
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months

JAGX : 0.2585 (-9.84%)

Barchart Exclusives

3 Cheapest Dividend Kings To Buy Today
This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar